{
    "organizations": [],
    "uuid": "2017689fb9ecc74d7cd897a7c80e9eb1fb95e37c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ultragenyx-posts-positive-topline/brief-ultragenyx-posts-positive-topline-results-of-phase-1-2-clinical-study-of-investigational-gene-therapy-dtx301-idUSFWN1QP0HY",
    "ord_in_thread": 0,
    "title": "BRIEF-Ultragenyx Posts Positive Topline Results Of Phase 1/2 Clinical Study Of Investigational Gene Therapy DTX301",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 7 (Reuters) - Ultragenyx Pharmaceutical Inc:\n* ULTRAGENYX ANNOUNCES POSITIVE TOPLINE RESULTS AND DMC REVIEW FROM FIRST COHORT OF PHASE 1/2 CLINICAL STUDY OF DTX301, AN INVESTIGATIONAL GENE THERAPY IN ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY\n* ULTRAGENYX PHARMACEUTICAL INC - ‍COHORT 2 PATIENT ENROLLMENT TO BEGIN IN MARCH 2018; DATA EXPECTED IN SECOND HALF OF 2018​\n* ULTRAGENYX PHARMACEUTICAL INC - ‍UREAGENESIS NORMALIZED IN ONE PATIENT AND FURTHER INCREASED BY 24 WEEKS​\n* ULTRAGENYX - ‍IN DTX301 COHORT 1, AS OF FEB 15, THERE WERE NO INFUSION-RELATED ADVERSE EVENTS & NO SERIOUS ADVERSE EVENTS REPORTED​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-07T21:20:00.000+02:00",
    "crawled": "2018-03-08T17:20:36.017+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "ultragenyx",
        "pharmaceutical",
        "inc",
        "ultragenyx",
        "announces",
        "positive",
        "topline",
        "result",
        "dmc",
        "review",
        "first",
        "cohort",
        "phase",
        "clinical",
        "study",
        "dtx301",
        "investigational",
        "gene",
        "therapy",
        "ornithine",
        "transcarbamylase",
        "otc",
        "deficiency",
        "ultragenyx",
        "pharmaceutical",
        "inc",
        "patient",
        "enrollment",
        "begin",
        "march",
        "data",
        "expected",
        "second",
        "half",
        "ultragenyx",
        "pharmaceutical",
        "inc",
        "normalized",
        "one",
        "patient",
        "increased",
        "ultragenyx",
        "dtx301",
        "cohort",
        "feb",
        "adverse",
        "event",
        "serious",
        "adverse",
        "event",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}